Literature DB >> 24813033

Prevalence and risk factors associated with tardive dyskinesia among Indian patients with schizophrenia.

Rashmin M Achalia1, Santosh K Chaturvedi2, Geetha Desai2, Girish N Rao2, Om Prakash3.   

Abstract

BACKGROUND: Tardive dyskinesia (TD) is one of the most distressing side effects of antipsychotic treatment. As prevalence studies of TD in Asian population are scarce, a cross-sectional study was performed to assess the frequency of TD in Indian patients with schizophrenia and risk factors of TD.
METHOD: Cross-sectional study of 160 Indian patients fulfilling the DSM-IV TR criteria for schizophrenia and who received antipsychotics for at least one year, were examined with two validated scales for TD. Logistic regression analyses were used to examine the relationship between TD and clinical risk factors.
RESULTS: The frequency of probable TD in the total sample was 26.4%. The logistic regression yielded significant odds ratios between TD and age, intermittent treatment, and total cumulative antipsychotic dose. The difference of TD between SGA and FGA disappeared after adjusting for important co-variables in regression analysis.
CONCLUSION: Indian patients with schizophrenia and long-term antipsychotic treatment have a high risk of TD, and TD is associated with older age, intermittent antipsychotic treatment, and a high total cumulative antipsychotic dose. Our study findings suggest that there is no significant difference between SGAs with regards to the risk of causing TD as compared to FGAs.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  First generation antipsychotics; Prevalence; Risk factors; Second generation antipsychotics; Tardive dyskinesia

Mesh:

Substances:

Year:  2014        PMID: 24813033     DOI: 10.1016/j.ajp.2013.12.010

Source DB:  PubMed          Journal:  Asian J Psychiatr        ISSN: 1876-2018


  4 in total

1.  Psychotropic Medications-Induced Tardive Dyskinesia and Associated Factors Among Patients with Mental Illness in Ethiopia.

Authors:  Assefa Kumsa; Shimelis Girma; Bezaye Alemu; Liyew Agenagnew
Journal:  Clin Pharmacol       Date:  2020-12-01

Review 2.  Treatment of Tardive Dyskinesia: A General Overview with Focus on the Vesicular Monoamine Transporter 2 Inhibitors.

Authors:  Nicki Niemann; Joseph Jankovic
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

Review 3.  Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review.

Authors:  Marco Solmi; Andrea Murru; Isabella Pacchiarotti; Juan Undurraga; Nicola Veronese; Michele Fornaro; Brendon Stubbs; Francesco Monaco; Eduard Vieta; Mary V Seeman; Christoph U Correll; André F Carvalho
Journal:  Ther Clin Risk Manag       Date:  2017-06-29       Impact factor: 2.423

4.  Assesment of Risk Factors for Tardive Dyskinesia.

Authors:  Melek Kanarya Vardar; Mehmet Emin Ceylan; Bariş Önen Ünsalver
Journal:  Psychopharmacol Bull       Date:  2020-07-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.